CliffBio
small molecule

SUNLENCA

LENACAPAVIR SODIUM

Loss of exclusivityAugust 2041latest FDA-listed patent expiry
CompanyGilead Sciences →See this company's full patent-cliff portfolio

Drug detail

Brand nameSUNLENCA
Active ingredientLENACAPAVIR SODIUM
StrengthEQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalDecember 2022
Marketing statusRX

Listed patents

PatentExpiresType
11944611August 2041use U-3507
12594267July 2039product
11267799August 2038substance
10654827August 2037use U-3507
10071985August 2037substance, product
9951043February 2034substance, product

Regulatory exclusivity

CodeExpires
NCEDecember 2027

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SUNLENCA patent cliff — loss of exclusivity August 2041 | CliffBio